Your browser doesn't support javascript.
loading
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; Cebon, Jonathan; Ferrucci, Pier Francesco; Aglietta, Massimo; Neyns, Bart; Chiarion-Sileni, Vanna; Lindsay, Colin R; Del Vecchio, Michele; Linardou, Helen; Merelli, Barbara; Tonini, Giuseppe; Atkinson, Victoria; Freivogel, Klaus; Stein, Dara; Dalland, Lindi; Lau, Mike; Legenne, Philippe; Queirolo, Paola; Millward, Michael.
Afiliación
  • Martin-Algarra S; Department of Medical Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
  • Hinshelwood R; Department of Medical Oncology, The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW.
  • Mesnage S; Auckland City Hospital, Auckland, New Zealand.
  • Cebon J; Olivia Newton-John Cancer Research Institute at Austin Hospital, Heidelberg, VIC.
  • Ferrucci PF; Melanoma Unit, European Institute of Oncology, Milano.
  • Aglietta M; Department of Medical Oncology, Candiolo Cancer Institute, University of Torino, Torino.
  • Neyns B; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Chiarion-Sileni V; Melanoma and Esophageal Cancer Unit, Istituto Oncologico Veneto, Istituto Di Ricovero e Cura a Carattere Scientifico, Padova.
  • Lindsay CR; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, and Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Del Vecchio M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Linardou H; First Department of Oncology, Metropolitan Hospital, Athens, Greece.
  • Merelli B; Department of Medical Oncology, ASST Papa Giovanni XXIII, Bergamo.
  • Tonini G; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.
  • Atkinson V; Gallipoli Medical Research Foundation, University of Queensland and Princess Alexandra Hospital, Brisbane, QLD.
  • Freivogel K; UBC, Lörrach, Germany.
  • Stein D; UBC, Montreal, QC, Canada.
  • Dalland L; Novartis Norge AS, Oslo, Norway.
  • Lau M; Novartis Pharma AG, Basel, Switzerland.
  • Legenne P; Novartis Pharma AG, Basel, Switzerland.
  • Queirolo P; UOC Oncologia Medica, IRCCS San Martino-IST, Genova, Italy.
  • Millward M; School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.
Melanoma Res ; 29(5): 527-532, 2019 10.
Article en En | MEDLINE | ID: mdl-31095039
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oximas / Neoplasias Cutáneas / Proteínas Proto-Oncogénicas B-raf / Imidazoles / Melanoma Tipo de estudio: Evaluation_studies / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Melanoma Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oximas / Neoplasias Cutáneas / Proteínas Proto-Oncogénicas B-raf / Imidazoles / Melanoma Tipo de estudio: Evaluation_studies / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Melanoma Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido